Gencove is set to validate screening tests that measure polygenic risk scores across populations using a phase I Small Business Innovation Research (SBIR) grant from the National Human Genome Research Institute, which is part of the U.S. National Institutes of Health (NIH).
The amount of the grant was not disclosed.
The company will use its low-pass whole genome sequencing platform and imputation algorithms to analyze genetic risk for common conditions, starting with coronary artery disease, Gencove said in an April 25 statement.
Gencove added that its technology is highly accurate across ethnic groups and can be scaled up to assess risk across large health systems.
